News Image

NASDAQ:NBIX, a strong growth stock, setting up for a breakout.

By Mill Chart

Last update: Jan 12, 2024

In this article we will dive into NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed NEUROCRINE BIOSCIENCES INC showing up in our strong growth, ready to breakout screen, which makes it worth to investigate a bit more.

Evaluating Growth: NASDAQ:NBIX

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:NBIX, the assigned 9 reflects its growth potential:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.32%, which is quite impressive.
  • The Earnings Per Share has been growing by 66.75% on average over the past years. This is a very strong growth
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.46%.
  • NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
  • The Earnings Per Share is expected to grow by 51.63% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.00% on average over the next years. This is quite good.

Assessing Health for NASDAQ:NBIX

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:NBIX, the assigned 7 for health provides valuable insights:

  • NBIX has an Altman-Z score of 10.38. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of NBIX (10.38) is better than 86.13% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.39 indicates that NBIX has no problem at all paying its short term obligations.
  • NBIX has a Quick Ratio of 2.34. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.

Understanding NASDAQ:NBIX's Profitability

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:NBIX, the assigned 8 is noteworthy for profitability:

  • Looking at the Return On Assets, with a value of 6.71%, NBIX belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
  • With an excellent Return On Equity value of 9.54%, NBIX belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 12.95%, NBIX belongs to the best of the industry, outperforming 97.12% of the companies in the same industry.
  • The last Return On Invested Capital (12.95%) for NBIX is above the 3 year average (12.37%), which is a sign of increasing profitability.
  • With an excellent Profit Margin value of 10.71%, NBIX belongs to the best of the industry, outperforming 96.28% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • NBIX's Operating Margin of 19.50% is amongst the best of the industry. NBIX outperforms 96.79% of its industry peers.
  • The Gross Margin of NBIX (97.82%) is better than 97.29% of its industry peers.

Looking at the Setup

Besides the Technical Rating, ChartMill assigns a Setup Rating to every stock to determine the degree of consolidation. This rating, ranging from 0 to 10, is updated daily and evaluates various short-term technical indicators. NASDAQ:NBIX currently holds a 7 as its setup rating, suggesting a particular level of consolidation in the stock.

NBIX has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately. A pullback is taking place, which may present a nice opportunity for an entry. There is a resistance zone just above the current price starting at 132.49. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 130.57, a Stop Loss order could be placed below this zone.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

Our latest full fundamental report of NBIX contains the most current fundamental analsysis.

For an up to date full technical analysis you can check the technical report of NBIX

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/19/2024, 7:06:04 PM)

After market: 132 0 (0%)

132

-0.54 (-0.41%)

NBIX News

News Image4 days ago - Sentia Medical Sciences, Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
News Image10 days ago - ChartmillWhy NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image10 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

News Image11 days ago - ChartmillFor those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

News Image16 days ago - ChartmillDon't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.

In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals.

News Image18 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

News Image24 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...

News Imagea month ago - Investor's Business DailyS&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

News Imagea month ago - Investor's Business DailyAI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

Three of the featured stocks are closing in on record highs.

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Participate at Virtual Investor Conferences in March

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming virtual investor conferences in March. Eiry Roberts, Chief Medical...

NBIX Links
Follow us for more